Hemophagocytic syndrome
MONDO:0015540Hemophagocytic syndrome (HPS) is a rare immune disease and a potentially life-threatening disorder characterized by cytokine storm and overwhelming inflammation causing fever, hepatosplenomegaly, cytopenia, hypertriglyceridemia, hyperferritinemia, and hemophagocytosis in bone marrow, liver, spleen or lymph nodes. It can be either primary due to a genetic defect (primary hemophagocytic lymphohistiocytosis), or secondary to malignancies, to infections, most commonly with viruses such as Epstein-Barr virus or cytomegalovirus, human immunodeficiency virus, or to autoimmune disorders such as systemic lupus erythematosus or adult-onset Still disease (secondary hemophagocytic lymphohistiocytosis).
Also known as: HLH, Hemophagocytic Lymphohistiocytosis, hemophagocytic lymphohistiocytosis, hemophagocytic syndrome, FHL, familial erythrophagocytic lymphohistiocytosis, familial hemophagocytic lymphohistiocytosis, familial histiocytic reticulosis
58 clinical trials for this condition and its sub-types, 38 tagged with Hemophagocytic syndrome itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Hemophagocytic syndrome
-
Secondary hemophagocytic lymphohistiocytosis 15 trials · 24 incl. sub-types
2 sub-types
-
Hereditary hemophagocytic lymphohistiocytosis 8 trials · 16 incl. sub-types
11 sub-types
- Chediak-Higashi syndrome 9 trials
- Griscelli syndrome type 2 1 trial
- Familial hemophagocytic lymphohistiocytosis 3 1 trial
- Hermansky-Pudlak syndrome 2 0 trials
- Hermansky-Pudlak syndrome 9 0 trials
- Familial hemophagocytic lymphohistiocytosis 2 0 trials
- Familial hemophagocytic lymphohistiocytosis 4 0 trials
- Familial hemophagocytic lymphohistiocytosis 5 0 trials
- Familial hemophagocytic lymphohistiocytosis type 1 0 trials
- Hemophagocytic lymphohistiocytosis due to RhoG deficiency 0 trials
- Hemophagocytic lymphohistiocytosis, familial, 6 0 trials
-
Chemotherapy plus immunotherapy tested against rare EBV-Driven immune storm
Disease control CompletedResearchers are testing a combination of L-DEP chemotherapy (aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) and a PD-1 antibody as initial treatment for people with Epstein-Barr virus-positive lymphoma-associated hemophagocytic lymphohistiocytosis, a rare an…
Sponsor: Beijing Friendship Hospital • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Gentler transplant shows promise for kids with blood diseases
Disease control CompletedThis study tests a milder chemotherapy and immune-suppressing regimen before a stem cell transplant for children and young adults with non-malignant blood disorders like sickle cell disease or immune deficiencies. The goal is to safely achieve donor cell engraftment with fewer si…
Phase 2 • Sponsor: Children's Hospital of Philadelphia • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New hope for rare immune disease: drug combo shows promise in small study
Disease control CompletedThis study tested a combination of two drugs—interferon-gamma monoclonal antibody and dexamethasone—in 22 adults with a severe immune condition called refractory secondary HLH. The goal was to see if the treatment helps patients recover and how safe it is. Participants received t…
Sponsor: Fudan University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo shows promise for kids with rare immune disease
Disease control CompletedThis study tested a drug called alemtuzumab (Campath) as a first treatment for children with hemophagocytic lymphohistiocytosis (HLH), a rare and life-threatening immune disorder. The goal was to see if it could help children survive until they could receive a stem cell transplan…
Phase 1/2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New drug shows promise for controlling rare immune disorder
Disease control CompletedThis study tested the drug ITACITINIB in 35 adults with a mild form of a rare immune disease called HLH. The goal was to see if the drug could control the disease by improving symptoms within 15 days. The trial is now complete, and results will show how well the drug works for th…
Phase 2 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New study aims to crack the code of autoimmune diseases
Knowledge-focused CompletedThis study is collecting blood, urine, and stool samples from 500 children with autoimmune diseases and healthy controls. Researchers will analyze these samples to find molecular patterns that could help diagnose these conditions and guide treatment decisions. The goal is to crea…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Scientists investigate rare immune disorder in adults to unlock diagnostic clues
Knowledge-focused CompletedThis completed study looked at 204 adults with hemophagocytic syndrome, a rare immune condition. Researchers aimed to identify biological markers and refine diagnosis criteria, which are currently based on children's genetics. The goal is to better understand the disease's causes…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC